Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Genentech
Ibandronic acid
Другие языки:

    Ibandronic acid

    Подписчиков: 0, рейтинг: 0
    Ibandronic acid
    Ibandronic acid.svg
    Clinical data
    Trade names Boniva, Bonviva, Bondronat, others
    AHFS/Drugs.com Monograph
    License data
    Pregnancy
    category
    • AU: B3
    Routes of
    administration    		 By mouth, intravenous
    ATC code
    Legal status
    Legal status
    • US: ℞-only
    • EU: Rx-only
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    Bioavailability 0.6%
    Protein binding 90.9 to 99.5%
    (concentration-dependent)
    Metabolism Nil
    Elimination half-life 10 to 60 hours
    Excretion Kidney
    Identifiers
    • Hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    PDB ligand
    CompTox Dashboard (EPA)
    ECHA InfoCard 100.214.537
    Chemical and physical data
    Formula C9H23NO7P2
    Molar mass 319.231 g·mol−1
    3D model (JSmol)
    • O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O
    • InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17) checkY
    • Key:MPBVHIBUJCELCL-UHFFFAOYSA-N checkY
     ☒NcheckY (what is this?)  (verify)

    Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodium salt ibandronate sodium.

    It was patented in 1986 by Boehringer Mannheim and approved for medical use in 1996.

    Medical uses

    Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.

    Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.

    Adverse effects

    In 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint or muscle pain. A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. The drug also has been associated with osteonecrosis of the jaw, relatively rare but serious condition.

    Pharmacology

    Relative potency
    Bisphosphonate Relative potency
    Etidronate 1
    Tiludronate 10
    Pamidronate 100
    Alendronate 100-500
    Ibandronate 500-1000
    Risedronate 1000
    Zoledronate 5000

    Brand names

    Ibandronic acid is marketed under the trade names Boniva in the US, Bondronat in Europe, Bonviva in Asia, Bandrone in India, Ibandrix in Ecuador, Adronil in Pakistan, Bondrova in Bangladesh and Bonprove in Egypt, Fosfonat in Mexico.

    External links


    Новое сообщение